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Abstract. An increasing number of immunocompromised individuals are pursuing international travel, and a better
understanding of their international travel patterns and pretravel health care is needed. We evaluated the clinical features,
itineraries, and pretravel health care of 486 immunocompromised international travelers seen at Global TravEpiNet
sites from January 2009 to June 2012. We used bivariate analyses and logistic regressions using random intercept
models to compare demographic and travel characteristics, vaccines administered, and medications prescribed for
immunocompromised travelers versus 30,702 immunocompetent travelers. Immunocompromised travelers pursued itin-
eraries that were largely similar to those of immunocompetent travelers, with nearly one-third of such travelers visiting
countries with low human development indices. Biological agents, including tumor necrosis factor blockers, were com-
monly used immunosuppressive medications among immunocompromised travelers. A strong collaboration between
travel-medicine specialists, primary care doctors, and specialist physicians is needed to prepare immunocompromised
people for international travel. Incorporating routine questioning and planning regarding travel into the primary care
visits of immunocompromised people may be useful.
INTRODUCTION
There were more than 60 million trips to foreign coun-
tries undertaken by U.S. citizens in 2013.1 Travel to coun-
tries with developing economies, such as those in Africa and
Asia, has increased over the past 20 years.2 Concurrently,
there has been an increase in the number of people living
with immune-compromising conditions, such as those receiv-
ing disease-modifying medications that suppress one or more
immune pathways, recipients of transplanted organs or stem
cells,3 and persons with late-stage human immunodeficiency
virus (HIV) infection.4 In a recent survey of U.S. solid-organ
transplant recipients, 27% reported travel outside the United
States or Canada.5 Similarly, a reported 20–46% of HIV-
infected patients travel internationally.6–8
A pretravel health consultation is particularly important
for the immunocompromised traveler, but may be challenging
for practitioners without extensive experience with immuno-
compromised patients. For instance, immunosuppression
influences clinical decision making about whether a traveler
should receive selected vaccines and also may affect the level
of immune protection achieved after immunization with both
routine and travel-related vaccines.9 Immunocompromised
people are at higher risk for travel-related complications and
have higher rates of hospitalization when travel-related illness
occurs.10,11 Pretravel planning, including ensuring an adequate
supply of routine medications and consideration of medical
evacuation insurance, is therefore particularly important for
these travelers.
A better understanding of the travel patterns and pre-
travel health care of immunocompromised people is needed
to inform specific guidance for such travelers and medical
providers who care for them. We evaluated a large cohort
of immunocompromised travelers who obtained pretravel
health advice in Global TravEpiNet (GTEN), a consortium
of U.S. practices that provide pretravel care to international
travelers. Our goals were to describe the demographics, itin-
eraries, and pretravel care of immunocompromised travelers
who sought pretravel health advice, to compare these charac-
teristics with immunocompetent travelers at these sites, and
to identify areas in which the pretravel preparation of this
population could be improved.
METHODS
Consortium description. GTEN is a U.S. Centers for Dis-
ease Control and Prevention (CDC)-supported consortium
of clinical practices that provide pretravel health care, as pre-
viously described.12 In brief, GTEN sites are distributed across
the United States and include academic practices, health-care
consortia, health-maintenance organizations, pharmacy-based
clinics, private practices, and public health clinics. Human sub-
ject advisors at each participating site reviewed and approved
or exempted the collection and subsequent analyses of the
de-identified data.
Data collection and description. Clinicians collected
de-identified data on all people seen for pretravel consul-
tation at 21 participating sites from January 2009 through
June 2012 by using a secure internet tool. For each unique
clinic visit, travelers provided details about their reasons for
seeking consultation, medical history, number of itineraries,
countries of planned travel, dates of travel, planned accommo-
dations, purpose(s) of travel, setting(s) of travel, and planned
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activities. Travelers selected one or more of the following
purposes for their trips: leisure, business, returning to region
of origin of self or family to visit friends and relatives, adop-
tion, providing medical care, receiving medical care, research/
education, nonmedical service work, missionary work, mili-
tary service, adventuring, attending large gatherings or events,
or other activities. Clinicians verified and further clarified, as
needed, the information provided by travelers and entered
additional data on immunization history, health advice pro-
vided, vaccines administered, and medications prescribed
during the pretravel encounter. If a traveler had an indica-
tion for a vaccine according to the Advisory Committee on
Immunization guidelines that were current at the time of the
clinic visit, but the vaccine was not administered, the clinician
was required to provide a reason for not administering the
vaccine; available options included preexisting immunity,
vaccine not indicated, referred to primary care provider for
vaccination, patient declined, medical contraindication, insuf-
ficient time, or vaccine not available.
Definition of immunocompromised travelers. We defined
an immunocompromised traveler as a person with one or
more of the following conditions: human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS),
organ or stem cell transplant, hematologic malignancy,
thymectomy, splenectomy, sickle cell anemia, or current
receipt of an immunosuppressive medication. Immuno-
suppressive medications were defined as corticosteroids
(equivalent to ≥ 20 mg prednisone/day), methotrexate, bio-
logical treatment agents that may suppress one or more
immune pathways (including tumor necrosis factor [TNF]
blockers, rituximab, and other potentially immunosup-
pressive biologic therapies), calcineurin inhibitors (cyclo-
sporine, tacrolimus), mycophenolate mofetil, antimetabolites
(azathioprine, 6-mercaptopurine), sirolimus, leflunomide,
hydroxyurea, alkylating agents, and immunosuppressive
cancer chemotherapy. We excluded patients from the analy-
sis if we were unable to determine the level of immuno-
suppression based on available data (e.g., a reported
non-hematological malignancy without treatment details or
steroids of unknown dose). All other travelers were classi-
fied as immunocompetent.
Classification of destination countries and visiting friends
and relatives travelers. We classified destination countries
in accordance with the 2011 U.N. Human Development
Index.13 In accordance with the CDC definition of the term,9
we defined a VFR (visiting friends and relatives) traveler as
a person who was traveling to a country with a low or
medium human development score and who selected “traveling
to region of origin of self or family to visit friends or relatives”
as his or her purpose of travel.
Data analysis. Data analyses were performed by using
SAS 9.3 (SAS Institute, Cary, NC) and Excel 2010 (Microsoft
Corporation, Redmond, WA). Bivariate analyses were done
by using χ2 test for categorical variables and Wilcoxon
rank-sum test for continuous variables. Logistic regressions
were used to test for associations between demographics,
travel characteristics, medicines, and immunosuppressed
status. Because of possible clinic variation, random inter-
cept models using clinic as the random effect with a correc-
tion for a small number of clusters were used.14 Statistical
significance was determined at a two-sided P value of 0.05
for all tests.
RESULTS
During the study period, 32,099 travelers were seen at 21
GTEN sites. Because the immune status of 911 people could
not be determined, these travelers were excluded from the
analysis. For the remaining 31,188 travelers included in the
analysis, we classified 486 (1.6%) as immunocompromised
and 30,702 as immunocompetent (98%). Use of an immuno-
suppressive medication, HIV/AIDS, and receipt of a solid-organ
transplant were the most common immmunocompromising
conditions in our study cohort (Table 1). Among the 110
HIV-positive travelers in the study, 71 (65%) had a CD4
count above 500 cells/mm3. Corticosteroids and TNF inhibi-
tors were the most commonly used immunosuppressive med-
ications (Table 1).
Immunocompromised travelers were older than the gen-
eral population of travelers (Table 2); 61 (13%) were over
the age of 65 years. India was the most frequent destination
country for both immunocompromised and immunocom-
petent travelers. Immunocompromised travelers traveled for
a similar length of time as immunocompetent travelers
(median, 14 days); both groups of travelers were seen a
median of 25 days before departure. Thirteen percent of
immunocompromised travelers were pursuing VFR travel,
and 19% were staying with relatives. Immunocompromised
travelers were more likely to travel on cruise ships than
immunocompetent travelers (8% versus 4%, P < 0.001;
Table 2). Immunocompromised travelers took a median
of three medications, which was significantly higher than
immunocompetent travelers (median of 1 medication).
We evaluated the travel characteristics of different types
of immunocompromised travelers (Table 3). Few solid-organ
transplant recipients traveled to countries with low U.N.
TABLE 1
Immunosuppressive conditions among immunocompromised travelers
in Global TravEpiNet*
















CD4 count > 500 71
CD4 count 200–500 22




Sickle cell anemia 9
Stem cell or bone marrow transplant 7
Neutropenia 5
Hypogammaglobulinemia 4
History of thymectomy or thymus disease 1
TNF = tumor necrosis factor.
*Patients can have ≥ 1 immunosuppressive condition or be taking more than one immuno-
suppressive medication.
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human development indices. Approximately half of HIV-
positive travelers (46% of those with CD4 < 500 and 51%
of those with CD4 > 500) were traveling to countries with a
low U.N. human development index. African countries were
the most common destinations among HIV-positive travelers,
whereas India was the most common travel destination
among other immunocompromised people. Leisure was the
most common purpose of travel for all groups, but HIV-positive
travelers and recipients of solid-organ transplants were com-
monly identified as VFR travelers. Of people taking TNF
blockers, almost one-quarter were pursuing business travel.
Overall, 93% of immunocompromised travelers were trav-
eling to countries where malaria is wholly or partially
endemic. Significantly fewer immunocompromised travelers
than immunocompetent travelers who were visiting malaria-
endemic countries were prescribed malaria chemoprophy-
laxis (281 [62%] versus 19,432 [69%], P = 0.001). Of the
108 immunocompromised travelers visiting countries wholly
TABLE 2





Number (% of total) 486 (1.6) 30,702 (98.4) –
Age (median, range) 46 (1.5–83) 35 (0–94) < 0.0001
Female 241 (50%) 16,672 (54%) 0.11
Destination (UNHDI classification)† 0.02
Low human development 138 (28%) 9,507 (31%) –
Medium human development 242 (50%) 14,852 (48%) –
High human development 84 (17%) 5,407 (18%) –
Very high human development 22 (5%) 936 (3%) –
Days to departure (median, range) 25 (0–424) 25 (0–564) 0.0004
Duration of travel (days; median, range) 14 (2–700) 14 (0–9999) 0.05
Purpose of travel§
Leisure 288 (59%) 16,563 (54%) 0.01
Business 80 (16%) 5,711 (19%) 0.05
VFR 62 (13%) 2,898 (9%) 0.29
Non-medical service work 13 (3%) 2,253 (7%) 0.002
Missionary work 20 (4%) 1,738 (6%) 0.36
Adventuring 15 (3%) 1,678 (6%) 0.003
Accommodations§
Camping 21 (4%) 2,213 (7%) 0.01
Dormitory or hostel 41 (8%) 5,191 (17%) < 0.0001
Home stay with relatives 92 (19%) 4,516 (15%) 0.07
Hotel 353 (73%) 21,239 (69%) 0.19
Cruise 38 (8%) 1,240 (4%) < 0.0001
Taking a medication currently 459 (94%) 17,584 (57%) < 0.0001
Number of medications per person (median, range) 3 (0–11) 1 (0–15) < 0.0001
UNHDI = United Nations Human Development Index; VFR = visiting friends and relatives.
*P value calculated via random intercept model.
†Travelers can travel to ≥ 1 destination.
‡All percentages are column percentages unless otherwise stated.
§Travelers could choose more than one purpose of travel or more than one accommodation.
TABLE 3






CD4 ≥ 500 cells/mm3
(N = 71)
CD4 < 500 cells/mm3
(N = 39)
Top destinations Kenya (8%) South Africa (15%) India (15%) India (18%)
Ghana (7%) Ghana (10%) China (10%) Thailand (10%)
Guinea (7%) India (8%) Italy (8%) Kenya (7%)
South Africa (7%) Peru (8%) Greece (7%) Cambodia (7%)
Senegal (8%)
Zambia (8%)
Travel to region with low human development
(UNHDI classification)*
33 (46%) 20 (51%) 5 (8%) 23 (32%)
Purpose of travel†
Leisure 36 (51%) 18 (46%) 31 (51%) 41 (56%)
Business 14 (20%) 6 (15%) 12 (20%) 17 (23%)
VFR 16 (23%) 16 (41%) 11 (18%) 2 (3%)
Non-medical service work 2 (3%) 0 1 (2%) 2 (3%)
Missionary work 1 (1%) 0 6 (10%) 1 (1%)
Adventuring 3 (4%) 1 (3%) 0 2 (3%)
Days before departure visited travel clinic
(median, range)
21 (0–257) 22 (4–98) 22 (0–252) 25 (0–353)
*United Nations Human Development Index (UNHDI).
†Visiting friends and relatives (VFR).
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endemic for malaria, 92 (85%) received malaria chemo-
prophylaxis. Atovaquone/proguanil was the most com-
monly prescribed agent for malaria chemoprophylaxis in
both immunocompromised and immunocompetent travelers.
Antibiotics for the presumptive self-treatment of travelers’
diarrhea were prescribed at a similar rate in the immuno-
compromised and immunocompetent populations (79% and
78%, respectively). Only 6% of immunocompromised trav-
elers were prescribed prophylactic antibiotics to prevent
traveler’s diarrhea, which was similar to the frequency in
immunocompetent travelers (7%).
Among the 486 immunocompromised travelers, typhoid
(75%) and hepatitis A (43%) were the most frequently
administered vaccines. Yellow fever (42% of the 149 immu-
nocompromised travelers to yellow fever-endemic countries)
and measles, mumps, and rubella (10% of the 486 immuno-
compromised travelers) were the vaccines that clinicians
most frequently considered to be contraindicated in immuno-
compromised travelers (Figure 1). Fifty-one (34%) of the
149 immunocompromised travelers who were visiting yellow
fever-endemic countries received the yellow fever vaccine;
29 (57%) of these travelers were HIV positive (83% of
whom had a CD4 count > 500 cells/mm3). Four patients on
TNF inhibitors received the yellow fever vaccine, and no
solid-organ transplant recipients received the yellow fever
vaccine. Seven percent of immunocompromised travelers,
as compared with 19% of immunocompetent travelers,
declined influenza vaccination that was suggested by the
clinician (Figure 1).
DISCUSSION
Our study is the largest to date to focus on pretravel care
of immunocompromised U.S. international travelers. The
travelers in our study had a range of immunocompromising
conditions, ranging from receipt of a solid-organ transplant
to prescription of low doses of methotrexate.9 In general,
immunocompromised travelers in our sample were pursuing
similar types of travel as immunocompetent travelers, and
our findings highlight that pretravel care and advice for these
travelers is complex. For instance, immunocompromised
people were taking multiple medications and medical contra-
indications to travel-related vaccination, such as yellow fever,
were common.
We found that travelers receiving biological agents, such
as TNF inhibitors, represented a large proportion of the
immunocompromised traveling population. TNF inhibitors
were among the most commonly used immunosuppressive
medication in our study, likely reflecting the increasing number
of indications for their use in recent years. Importantly, these
medications increase the risk for severe complications of cer-
tain infections that may be related to travel, including tuber-
culosis, endemic mycoses, non-typhoidal salmonellosis, and
leishmaniasis.15–18 Vaccine responses, particularly to influenza
and pneumococcal vaccines, may be diminished in people
taking TNF blockers, but vaccination is nevertheless recom-
mended.19–21 Live-virus vaccination is contraindicated in
people receiving immune-modulating agents, such as TNF
blockers. Travel medicine practitioners and others caring for
immunocompromised travelers need to be familiar with the
immunosuppressive effects resulting from these medications.22
The purposes of travel and destinations of immunocom-
promised travelers were generally similar to the overall traveling
population in our study. Leisure travel, including to regions
of low socioeconomic development, was common in both
groups. Destination countries were similar in both groups,
with India being themost popular destination overall. However,
there were some notable differences between the itineraries
of immunocompromised and immunocompetent travelers.
Solid-organ transplant recipients were less likely to travel to
FIGURE 1. Vaccine receipt in immunocompromised travelers (IC) and immunocompetent travelers (notIC).
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countries with low U.N. human development indices and
more likely to engage in cruise ship travel, perhaps reflecting
more caution among this group of travelers. VFR travel was
particularly common among HIV-infected travelers, and HIV-
infected travelers were more frequently visiting countries in
Africa, including South Africa, Ghana, and Kenya. Immuno-
compromised people traveled to countries with malarious
areas at similar frequencies to immunocompetent travelers
but were less likely to be prescribed malaria chemoprophylaxis.
This may reflect the pursuit of more cautious itineraries, or
alternatively, concern about drug–drug interactions.
Vaccine receipt differed between immunocompromised
and immunocompetent travelers. Although many immuno-
compromised travelers were visiting countries with yellow
fever virus transmission, a lower proportion of immunocom-
promised than immunocompetent travelers received the yellow
fever vaccine. This likely reflects the fact that immunosup-
pression is a contraindication for yellow fever vaccination,
but also may suggest more caution regarding itinerary choice
among immunocompromised travelers, who may choose to
travel to areas without yellow fever when traveling to countries
such as Peru and Brazil, where yellow fever virus circulation
is not uniformly endemic. The majority of the immunocom-
promised travelers in this study who received the yellow
fever vaccine were HIV-positive people with CD4 count
≥ 500 cells/mm3; this practice is consistent with CDC guidelines,
which consider asymptomatic HIV infection and HIV infection
with CD4 count of 200–499 cells/mm3 to be a precaution but
not a contraindication for yellow fever vaccine administration.9
Many immunocompromised and immunocompetent travelers
in this study refused influenza vaccination. Some studies
have evaluated the immunogenicity of influenza vaccine
in HIV-infected individuals,23–25 but in general, there are few
data on immune responsiveness to travel vaccines in the various
subsets of immunocompromised travelers. More research
in this area is needed given the frequency of travel in
this population.
Our findings identify a few areas where the care of immu-
nocompromised travelers might be improved. First, immuno-
compromised travelers in this study were seen a median of
25 days before departure; this indicates that many immuno-
compromised travelers did not have enough time to complete
certain travel-related vaccination series, such as for rabies and
Japanese encephalitis. Strategies to optimize the timing of
pretravel preparation for immunocompromised travelers are
important; incorporating routine questioning and planning
regarding travel into the primary-care visits of immunocom-
promised people may be one approach. Immunocompro-
mised business travelers would be a particularly important
target for routine pretravel planning, since last-minute travel
is more common among business travelers.12 Another potential
area for improvement is the uptake of influenza vaccine
among immunocompromised travelers. Influenza vaccination
is universally recommended in the United States for people
> 6 months of age,26 and the pretravel consultation represents
an opportunity to update adult vaccines for all people.27
Immunocompromised people are at particular risk of influenza-
related complications,28 so more effective strategies to educate
immunocompromised people about influenza and increased
vaccine uptake are needed. Notably, we found that cruise
ship travel was favored by certain immunocompromised
travelers. Outbreaks of respiratory infections and gastroenteritis
have been reported on cruise ships29–31 and immunocompro-
mised travelers should be counseled by their health-care pro-
viders about strategies for avoiding illness in such settings,
such as handwashing. Finally, many travelers in this study
were traveling to destinations with limitedmedical infrastructure;
a reliable supply of medications and purchase of medical
evacuation insurance should be considered for all immuno-
compromised travelers.
Our study has a few notable limitations. Data were captured
by practicing clinicians, but certain details regarding the
degree of immune compromise were lacking and hence a
large number of people could not be fully classified for the
purposes of this study. The full details of the clinical decision-
making process were also not available. Our study does not
consider people with less severe degrees of immunosuppression,
including advanced chronic kidney disease, cirrhosis of the
liver, diabetes, older age, and other chronic debilitatingmedical
conditions. GTEN sites include a variety of practice settings,
many of which specialize in travel medicine; although we
anticipate that immunocompromised travelers may be more
likely to seek pretravel care at specialized clinics, the charac-
teristics of immunocompromised travelers seen in other settings
may differ from those of people in our study. In particular,
immunocompromised travelers traveling to areas of higher
development may more commonly seek pretravel consultation
in primary care settings.
In conclusion, our results indicate that immunocompromised
travelers are pursuing itineraries that are largely similar to
those of immunocompetent travelers. Pretravel preparation
of the immunocompromised traveler is complex and requires
expertise in vaccination, drug interactions, and the nature of
various immunocompromising conditions.A strong collaboration
between travel-medicine specialists, primary-care doctors,
and specialist physicians caring for immunocompromised
people is needed to help them make appropriate selections
on itinerary, vaccinations, and chemoprophylaxis.
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